Response to Medication Registry

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

196 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-03-31

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To create a registry/database of patients who either have taken drugs that treat cardiovascular conditions or that have presented with cardiovascular symptoms that may be related to medication.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Diagnosing Adverse Drug Reactions Registry

NCT01970709

Genetics of Drug Metabolism

UNKNOWN

An Open-label, Single-centre Study Evaluating the Pharmacokinetics of Digoxin Alone and When Administered at Various Doses of Ezogabine/Retigabine in Healthy Adults. The Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR) Will Also be Assessed

NCT01583036

Epilepsy

COMPLETED PHASE1

Evaluate the Effects of Renal Impairment on the Pharmacokinetics and Pharmacodynamics

NCT05323136

ACS - Acute Coronary Syndrome

TERMINATED PHASE1

A Study of the Effect of Multiple Doses of Diltiazem on the Plasma Levels of MK-6916 in Healthy Participants (MK-6916-005)

NCT06818968

Healthy

COMPLETED PHASE1

A Study of the Effect of Diltiazem on the Plasma Levels of Nemtabrutinib (MK-1026-022)

NCT07232589

Healthy

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To create a registry/database of patients who either have taken drugs that treat cardiovascular conditions or that have presented with cardiovascular symptoms that may be related to medication. Potential enrollees are those receiving (presently or in the past) the medicine(s) of interest. Subjects will be identified from computerized Intermountain Healthcare records. Patients receiving a drug of interest, both with and without an ADE will be enrolled in approximately equal numbers. Outpatients will be contacted by mail and invited to participate. Interested subjects will be instructed to return the enclosed response card with their intent indicated. The registry coordinator will contact interested subjects and the project will be explained. Willing participants will be enrolled either in person or via mail with the assistance of the project coordinator. Persons presenting in person for enrollment will be given the choice of venipuncture or buccal swab for sample collection for DNA extraction. In all cases informed consent will be obtained before collecting samples.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Adverse Drug Events

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patient must be \> 18 years of age.
* The patient or legally authorized representative must sign a written informed consent, prior to sample collection, using a form that is approved by the local Institutional Review Board.
* The patient must have taken a medication of interest or have presented with a cardiovascular symptom possibly related to medication. The current medications of interest are as follows:

* ACE inhibitors
* ARBs
* Aldosterone Antagonists
* Alpha-Andrenergic Agonists
* Anticoagulants
* B-Type Natriuretic Peptides
* Beta-blockers
* Calcium Channel Blockers
* Cardiac Glycosides
* Antiarrhythmics
* Combination Drugs
* Diuretics
* Electrolyte/Mineral Replacements
* Lipid-lowering Medications
* Positive Inotropes
* Vasodilators/Nitrates
* Statins
* Antibiotics
* Anthrocyclines

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No